Currently out of the existing stock ratings of Matthew Luchini, 46 are a HOLD (36.22%), 81 are a BUY (63.78%).

Matthew Luchini

Work Performance Price Targets & Ratings Chart

Analyst Matthew Luchini, currently employed at BMO, carries an average stock price target met ratio of 41.84% that have a potential upside of 22.14% achieved within 121 days.

Matthew Luchini’s has documented 270 price targets and ratings displayed on 25 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on REPL, Replimune Group at 18-Mar-2022.

Wall Street Analyst Matthew Luchini

Analyst best performing recommendations are on BLUE (BLUEBIRD BIO).
The best stock recommendation documented was for BLUE (BLUEBIRD BIO) at 6/6/2017. The price target of $69.95 was fulfilled within 1 day with a profit of $6.38 (10.04%) receiving and performance score of 100.36.

Average potential price target upside

of $53.49 (12.39%) on REGN (REGENERON PHARMACEUTICALS).
of $37 (34.25%) on ALXN (ALEXION PHARMACEUTICALS).
of $23.66 (33.56%) on KOD (KODIAK SCIENCES).

AGTC Applied Genetic ALXN Alexion Pharmaceuticals APLS Apellis Pharmaceuticals ARVN Arvinas BLUE Bluebird bio CCCC C4 Therapeutics GILD Gilead Sciences ICPT Intercept Pharmaceuticals IFRX InflaRx N.V. KOD Kodiak Sciences MDGL Madrigal Pharmaceuticals NG NovaGold Resources NGM NGM Biopharmaceuticals REGN Regeneron Pharmaceuticals TCRR Tcr2 Therapeutics ONCE Spark Therapeutics DBTX Decibel Therapeutics JSPR Jasper Therapeutics ETTX Entasis Therapeutics Holdings REPL Replimune Group AGLE Aeglea Bio Therapeutics BOLD Audentes Therapeutics MITO Stealth BioTherapeutics Corp ALDR Alder BioPharmaceuticals RGLS Regulus Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Joseph Pantginis (HC WAINWRIGHT)